Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 6 | 2022 | 182 | 1.180 |
Why?
|
| Renal Dialysis | 4 | 2008 | 171 | 0.730 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2007 | 30 | 0.720 |
Why?
|
| Kidney Failure, Chronic | 5 | 2008 | 200 | 0.710 |
Why?
|
| Postanesthesia Nursing | 3 | 2004 | 9 | 0.660 |
Why?
|
| Liver Transplantation | 2 | 2023 | 155 | 0.360 |
Why?
|
| Immunosuppressive Agents | 4 | 2004 | 223 | 0.330 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2008 | 13 | 0.310 |
Why?
|
| Graft Rejection | 3 | 2022 | 168 | 0.280 |
Why?
|
| Postoperative Care | 2 | 2004 | 105 | 0.280 |
Why?
|
| Hydrastis | 3 | 2015 | 10 | 0.270 |
Why?
|
| Postoperative Complications | 2 | 2003 | 1035 | 0.260 |
Why?
|
| Vascular Diseases | 2 | 2004 | 74 | 0.250 |
Why?
|
| Herb-Drug Interactions | 4 | 2008 | 31 | 0.240 |
Why?
|
| Anesthesia, Conduction | 1 | 2004 | 16 | 0.220 |
Why?
|
| Recovery Room | 1 | 2003 | 6 | 0.220 |
Why?
|
| Transplantation | 1 | 2003 | 14 | 0.220 |
Why?
|
| Arm | 1 | 2003 | 48 | 0.220 |
Why?
|
| Transplants | 1 | 2023 | 19 | 0.220 |
Why?
|
| Anesthesia, General | 1 | 2004 | 99 | 0.210 |
Why?
|
| Sirolimus | 1 | 2003 | 62 | 0.210 |
Why?
|
| Digoxin | 3 | 2008 | 30 | 0.210 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 122 | 0.190 |
Why?
|
| Critical Care | 1 | 2004 | 215 | 0.190 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 32 | 0.190 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 57 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 28 | 0.190 |
Why?
|
| Tacrolimus | 1 | 2002 | 54 | 0.190 |
Why?
|
| Thrombosis | 1 | 2003 | 249 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2002 | 170 | 0.170 |
Why?
|
| Humans | 22 | 2023 | 50389 | 0.160 |
Why?
|
| Kidney | 1 | 2003 | 686 | 0.160 |
Why?
|
| Dietary Supplements | 4 | 2015 | 445 | 0.130 |
Why?
|
| Benzylisoquinolines | 1 | 2015 | 4 | 0.120 |
Why?
|
| Adult | 8 | 2008 | 13568 | 0.110 |
Why?
|
| Nurse's Role | 2 | 2004 | 67 | 0.110 |
Why?
|
| Biopsy | 2 | 2022 | 592 | 0.110 |
Why?
|
| Clarithromycin | 3 | 2008 | 38 | 0.110 |
Why?
|
| Rifampin | 3 | 2008 | 62 | 0.110 |
Why?
|
| Graft Survival | 2 | 2022 | 153 | 0.100 |
Why?
|
| Female | 12 | 2023 | 26981 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2022 | 6223 | 0.100 |
Why?
|
| Echinacea | 2 | 2008 | 5 | 0.100 |
Why?
|
| Hypericum | 2 | 2008 | 13 | 0.100 |
Why?
|
| Kava | 2 | 2008 | 11 | 0.090 |
Why?
|
| Cimicifuga | 2 | 2008 | 8 | 0.080 |
Why?
|
| Hypertension | 2 | 2004 | 550 | 0.080 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Male | 9 | 2015 | 25718 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2008 | 42 | 0.080 |
Why?
|
| Gadolinium | 1 | 2008 | 46 | 0.080 |
Why?
|
| Liver | 2 | 2022 | 1123 | 0.070 |
Why?
|
| Contrast Media | 1 | 2008 | 190 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2006 | 16 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2008 | 166 | 0.070 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 82 | 0.070 |
Why?
|
| Sulfates | 1 | 2006 | 24 | 0.060 |
Why?
|
| Genistein | 1 | 2006 | 46 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2005 | 39 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 409 | 0.060 |
Why?
|
| Middle Aged | 5 | 2008 | 12460 | 0.060 |
Why?
|
| Isoflavones | 1 | 2006 | 87 | 0.060 |
Why?
|
| Aged | 4 | 2007 | 9590 | 0.060 |
Why?
|
| Perioperative Nursing | 1 | 2004 | 7 | 0.060 |
Why?
|
| Urodynamics | 1 | 2004 | 23 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 102 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 1 | 2004 | 52 | 0.060 |
Why?
|
| Malignant Hyperthermia | 1 | 2004 | 8 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2004 | 75 | 0.060 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2004 | 20 | 0.060 |
Why?
|
| Axillary Vein | 1 | 2003 | 5 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 209 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2004 | 23 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2003 | 16 | 0.060 |
Why?
|
| Hypothermia | 1 | 2004 | 34 | 0.060 |
Why?
|
| Polytetrafluoroethylene | 1 | 2003 | 32 | 0.060 |
Why?
|
| Anesthesia Recovery Period | 1 | 2003 | 10 | 0.060 |
Why?
|
| Nephrosclerosis | 1 | 2003 | 4 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2003 | 8 | 0.050 |
Why?
|
| Airway Obstruction | 1 | 2004 | 46 | 0.050 |
Why?
|
| Models, Nursing | 1 | 2003 | 16 | 0.050 |
Why?
|
| Delirium | 1 | 2004 | 49 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2003 | 83 | 0.050 |
Why?
|
| Catheterization | 1 | 2004 | 101 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 163 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2003 | 95 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2004 | 266 | 0.050 |
Why?
|
| Living Donors | 1 | 2003 | 23 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2003 | 86 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 96 | 0.050 |
Why?
|
| Esophageal Perforation | 1 | 2002 | 3 | 0.050 |
Why?
|
| Delayed Graft Function | 1 | 2022 | 10 | 0.050 |
Why?
|
| Cold Ischemia | 1 | 2022 | 9 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2002 | 24 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 402 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 144 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2003 | 241 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2003 | 112 | 0.050 |
Why?
|
| Pancreas Transplantation | 1 | 2002 | 22 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 59 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1029 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2002 | 65 | 0.050 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2002 | 50 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2002 | 136 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 460 | 0.050 |
Why?
|
| ROC Curve | 1 | 2022 | 239 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 590 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 2219 | 0.050 |
Why?
|
| Reoperation | 1 | 2003 | 457 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 279 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2015 | 432 | 0.040 |
Why?
|
| Smoking | 1 | 2003 | 508 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 201 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 915 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 229 | 0.040 |
Why?
|
| Stents | 1 | 2002 | 347 | 0.040 |
Why?
|
| Infant | 1 | 2004 | 3601 | 0.030 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2015 | 11 | 0.030 |
Why?
|
| Drug Stability | 1 | 2015 | 34 | 0.030 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2015 | 11 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 167 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 229 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 237 | 0.030 |
Why?
|
| United States | 1 | 2003 | 4913 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 704 | 0.030 |
Why?
|
| Child | 1 | 2004 | 6877 | 0.020 |
Why?
|
| Ginkgo biloba | 1 | 2008 | 7 | 0.020 |
Why?
|
| Flavonoids | 1 | 2008 | 39 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 42 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 55 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2006 | 77 | 0.020 |
Why?
|
| Naphthols | 1 | 2006 | 9 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2006 | 208 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 4 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 462 | 0.020 |
Why?
|
| Sulfotransferases | 1 | 2006 | 39 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 85 | 0.020 |
Why?
|
| Haplotypes | 1 | 2005 | 82 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 456 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 179 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 369 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 975 | 0.010 |
Why?
|
| Aortic Rupture | 1 | 2002 | 18 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 1582 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 664 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 671 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 438 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 3287 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 1160 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 6475 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 13173 | 0.010 |
Why?
|